Table 1 Clinical characteristics of the participants
Group | Plasma | PBMC | ||||
|---|---|---|---|---|---|---|
HCa | BD | DC | HCa | BD | DC | |
(N=18) | (N=40) | (N=17) | (N=18) | (N=29) | (N=19) | |
Age (years), mean ± SD | 45 ± 7.7 | 44 ± 8 | 46 ± 11.7 | 45 ± 7.7 | 47 ± 9.7 | 46 ± 12.5 |
Age at BD diagnosis (years), mean ± SD | 34 ± 7.3 | 36 ± 13.6 | 37 ± 9.4 | 38 ± 12.8 | ||
Sex | ||||||
Male, N (%) | 2 (11.1) | 21 (52.5) | 6 (35.3) | 2 (11.1) | 18 (62.1) | 8 (42.1) |
Female, N (%) | 16 (88.9) | 19 (47.5) | 11 (64.7) | 16 (88.9) | 11 (37.9) | 11 (57.9) |
BMI | 23 ± 3.2 | 24 ± 3.0 | 24 ± 2.7 | 23 ± 3.2 | 22 ± 3.3 | 24 ± 1.8 |
Disease characteristics | ||||||
Oral aphthous ulcers, N (%) | 0 (0) | 39 (97.5) | 17 (100) | 0 (0) | 28 (96.6) | 19 (100) |
Genital ulcers, N (%) | 0 (0) | 29 (72.5) | 7 (41.2) | 0 (0) | 18 (62.1) | 3 (15.8) |
Skin lesions, N (%) | 0 (0) | 37 (92.5) | 12 (70.6) | 0 (0) | 27 (93.1) | 14 (73.7) |
Uveitis, N (%) | 0 (0) | 14 (35) | 1 (5.9) | 0 (0) | 12 (41.4) | 1 (5.3) |
Arthritis, N (%) | 0 (0) | 6 (15) | 1 (5.9) | 0 (0) | 2 (6.9) | 1 (5.3) |
GI lesions, N (%) | 0 (0) | 1 (2.5) | 2 (11.8) | 0 (0) | 1 (3.4) | 3 (15.8) |
CNS lesions, N (%) | 0 (0) | 2 (5) | 1 (5.9) | 0 (0) | 1 (3.4) | 1 (5.3) |
Vascular involvement, N (%) | 0 (0) | 8 (20) | 0 (0) | 0 (0) | 6 (20.7) | 0 (0) |
Dyslipidemia, N (%) | 5 (27.8) | 3 (7.5) | 1 (5.9) | 5 (27.8) | 0 (0) | 1 (5.3) |
Positive ANA, N (%) | 0 | 32 | 17 | 0 | 8 (27.6) | 19 |
Pathergy test | 0 (0) | 10 (31.3) | 1 (5.9) | 0 (0) | 21 | 1 (5.3) |
Positive pathergy, N (%) | 0 (0) | 3 (7.5) | 1 (5.9) | 0 (0) | 9 (42.9) | 1 (5.3) |
HLA-B51 test | 0 | 37 | 17 | 0 | 28 | 17 |
Positive, N (%) | 0 (0) | 19 (51.4) | 8 (47.1) | 0 (0) | 15 (53.6) | 7 (41.2) |
Negative, N (%) | 0 (0) | 18 (45) | 9 (52.9) | 0 (0) | 13 (44.8) | 10 (52.6) |
Previous treatment | ||||||
Systemic steroids, N (%) | 0 (0) | 9 (22.5) | 1 (5.9) | 0 (0) | 4 (13.8) | 0 (0) |
Colchicine, N (%) | 0 (0) | 25 (62.5) | 5 (29.4) | 0 (0) | 24 (82.8) | 2 (10.5) |
Azathioprine, N (%) | 0 (0) | 6 (15) | 0 (0) | 0 (0) | 5 (17.2) | 0 (0) |
Salazopyrine, N (%) | 0 (0) | 7 (17.5) | 0 (0) | 0 (0) | 9 (31) | 0 (0) |
Pentoxyphylline, N (%) | 0 (0) | 14 (35) | 5 (29.4) | 0 (0) | 19 (65.5) | 2 (10.5) |
Cilostazol, N (%) | 0 (0) | 3 (7.5) | 0 (0) | 0 (0) | 2 (6.9) | 0 (0) |
Antibiotic, N (%) | 0 (0) | 6 (15) | 0 (0) | 0 (0) | 5 (17.2) | 0 (0) |
Statin, N (%) | 0 (0) | 2 (5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |